Stocky turns companies like MoonLake Immunotherapeutics into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. Melilotus trades on modest fundamentals (26/100 Value Compounder Score) and carries material structural risk: the SLK IP license with MHKDG faces termination exposure if diligence milestones slip, while the Pichia pastoris sublicense with RCT adds manufacturing dependency. Leadership alignment (55/100) shows no founder-CEO lock-in or capped dilution signals. Investors require clarity on license compliance cadence and alternative IP pathways before higher conviction.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for MoonLake Immunotherapeutics:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 41/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates MoonLake Immunotherapeutics (MLTX) at 41/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. Melilotus trades on modest fundamentals (26/100 Value Compounder Score) and carries material structural risk: the SLK IP license with MHKDG faces termination exposure if diligence milestones slip, while the Pichia pastoris sublice
MLTX's current Stocky Verdict is 41/100, placing it in the "Cautious" band. This composite combines a 26/100 Compounder score, 55/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for MoonLake Immunotherapeutics yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
MoonLake Immunotherapeutics scores 55/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
MoonLake Immunotherapeutics's Vulnerability Profile scores 75/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to MoonLake Immunotherapeutics.
Sign up free and unlock the full analysis on MLTX — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for MLTX in the app.
